InflaRx N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IFRX Nasdaq 2836 www.inflarx.de

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for InflaRx N.V.

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor - Apr 9th, 2026 5:30 am
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization - Apr 7th, 2026 1:35 pm
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - Mar 31st, 2026 5:30 am
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - Mar 30th, 2026 5:30 am
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Mar 19th, 2026 6:45 am
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - Mar 19th, 2026 5:30 am
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - Mar 18th, 2026 5:30 am
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Mar 13th, 2026 3:00 pm
InflaRx to Report Full Year 2025 Results on March 19, 2026 - Mar 12th, 2026 5:30 am
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference - Feb 26th, 2026 5:30 am
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference - Feb 26th, 2026 4:54 am
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit - Feb 13th, 2026 8:02 pm
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely - Feb 2nd, 2026 4:04 am
InflaRx Announces Participation in February Investor Conferences - Jan 29th, 2026 5:30 am
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - Jan 8th, 2026 6:00 am
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - Dec 30th, 2025 5:30 am
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 - Dec 11th, 2025 5:30 am
Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion - Nov 18th, 2025 8:20 am
InflaRx (IFRX) Is Up 17.7% After INF904 Shows Promising Results in Phase 2a Study—What's Changed - Nov 12th, 2025 7:10 pm
BC-Most Active Stocks - Nov 10th, 2025 8:30 am